BRISBANE, Calif.--(BUSINESS WIRE)--Jun 30, 2026--
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the closing of the previously announced sale of its Lab Products business to Eurobio Scientific. The transaction closed on June 30, 2026 following receipt of required Swedish regulatory clearance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630207907/en/
Under the terms of the agreement, CareDx received $171.2 million in cash consideration at closing, subject to customary post-closing adjustments. The transaction includes CareDx’s Lab Products business of IVD (in vitro diagnostic) PCR kits for rapid deceased donor HLA (human leukocyte antigen) typing, IVD NGS-based (next-generation sequencing) kits for transplant recipient HLA typing globally, and IVD NGS-based monitoring assays for solid organ and stem cell transplant recipients outside of North America.
“This transaction sharpens CareDx’s focus on our core U.S. Precision Medicine Testing Services and Patient and Digital Solutions, where our integrated model continues to deliver strong growth,” said John Hanna, President and Chief Executive Officer of CareDx. “It also simplifies our operating model and supports our disciplined approach to capital allocation, including investments that expand our capabilities in high-growth areas such as specialty oncology.”
The Company anticipates providing additional details regarding the financial impact of the transaction, including pro forma results, during its second quarter 2026 earnings call.
CareDx is represented by Rothschild & Co. and Fenwick & West LLP. Eurobio Scientific is represented by TD Cowen and Kahn Partners in this transaction.
About CareDx
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non‑invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics‑based information for transplant patients. For more information, please visit www.caredx.com.
About Eurobio Scientific
Eurobio Scientific is a specialty in vitro diagnostics company focused on transplantation, immunology, and infectious diseases, with a broad portfolio of proprietary products and a global distribution network. For further information, visit: www.eurobio-scientific.com
Forward Looking Statements
This press release includes forward-looking statements related to CareDx including statements regarding the expected completion and timing of the divestiture, the anticipated impact of the transaction on CareDx’s business, financial profile, and operating results, the expected use of proceeds, the achievement of CareDx’s financial and operational goals and its expectations and prospects for 2026, and other statements that are not historical facts. These forward‑looking statements are based on information currently available to CareDx and its current expectations, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the failure to obtain required regulatory approvals or satisfy closing conditions, delays in completing the transaction, general economic and market factors, and other risks discussed in CareDx’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by CareDx with the SEC on February 25, 2026, and other reports that CareDx has filed with the SEC. Any of these risks may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
NEW YORK (AP) — U.S. stocks rose and trimmed their losses in what had been a rocky June. The S&P 500 gained 0.8% Tuesday, though it still fell to its first losing month following two fabulous ones. The Dow Jones Industrial Average added 0.3% to another record, and the Nasdaq composite climbed 1.5%. Stocks in the artificial-intelligence industry were strong following sharp swings earlier in the month on worries they’d grown too expensive. Treasury yields rose in the bond market as oil prices eased. Stock indexes rose in much of Europe and Asia, while the Japanese yen fell near a 40-year low against the U.S. dollar.
THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below.
NEW YORK (AP) — U.S. stocks are trimming their losses from a rocky June on Tuesday.
The S&P 500 rose 0.8%, though it's still heading for its first losing month following two fabulous ones. The Dow Jones Industrial Average was up 140 points, or 0.3%, as of 2:20 p.m. Eastern time, and the Nasdaq composite was 1.4% higher.
The main reason for this month’s weakness has been a fall to Earth for stocks in the artificial-intelligence industry. After soaring to tremendous heights in the frenzy around AI, such stocks have come under pressure because of worries that they shot too high. That’s a big deal for all investors because AI stocks have grown into some of Wall Street’s largest and most influential, pulling indexes behind them.
AI stocks were stronger Tuesday, with Nvidia rising 2% to trim its loss for the month. It was one of the strongest forces lifting the S&P 500.
Microsoft, which is investing heavily in AI, rose 0.6% to bring its loss for the month back below 18%. Oracle, though, fell 0.8% to bring its drop for June to 35%. It's another company contending with concerns that big spending on AI may not yield enough productivity and profits to make it worth it.
Outside of AI, the economy seems to be rumbling along, even though U.S. households are still feeling sour about it. A report released in the morning said that U.S. employers were advertising many more job openings at the end of May than economists expected, the latest signal that the job market remains resilient.
But a second report said that confidence among U.S. consumers improved by less than economists expected. More Americans are saying it's hard to get a job, according to a survey by the Conference Board, even with data suggesting continued hiring.
Tuesday's relatively quiet trading came as companies close their books for the quarter running from April through June. Investors want to see strong growth in profits to justify the big gains stocks made early in the quarter. Despite June’s drop, the S&P 500 is still on track for its best quarter since six years ago, when stocks rocketed out of the crash caused by the COVID pandemic.
Concentrix tumbled 13.1% after the technology company reported profit and revenue for the latest quarter that were just shy of analysts’ expectations.
In the oil market, prices drifted as two U.S. envoys arrived in Qatar for talks with mediators about the implementation of an initial deal to end the war in Iran. The Americans will not be having direct negotiations with Iranian diplomats while in Doha.
The price for a barrel of Brent crude oil, the international standard, erased an early, modest rise and fell 1.1% to $73.12. The hope is that an end to the war will restore full access to the Strait of Hormuz, allowing oil tankers to move more crude and lower its price.
Expensive oil has already sent inflation jumping around the world, which in turn has raised worries that the Federal Reserve and other central banks may have to raise interest rates. Higher rates would keep a lid on inflation, but they would also slow economic growth and hurt prices for investments.
The yield on the 10-year Treasury rose to 4.41% from 4.38% late Monday.
In stock markets abroad, indexes rose across much of Europe and Asia.
Germany’s DAX returned 1.5%, and South Korea’s Kospi climbed 1% for two of the world's bigger gains.
Japan’s Nikkei 225 rose 0.9% as the value of the Japanese yen dropped near its lowest level against the U.S. dollar in 40 years.
U.S. government bonds are paying much higher yields than their Japanese counterparts, and the possibility of rate hikes by the Fed is putting more pressure on the yen. Speculation is rising that Japan’s government may try to prop up the yen’s value, but Japan’s finance minister said only that the government was ready to “respond appropriately whenever necessary.”
AP Business Writers Chan Ho-him and Elaine Kurtenbach contributed to this report.
Specialist Michael Pistillo works on the floor of the New York Stock Exchange, Friday, June 26, 2026. (AP Photo/Richard Drew)
A man walks past a monitor showing stock prices of companies on the Tokyo Stock Exchange in Tokyo, Tuesday, June 23, 2026. (AP Photo/Hiro Komae)
A huge screen shows the Korea Composite Stock Price Index (KOSPI) and the foreign exchange rate between U.S. dollar and South Korean won at a dealing room of Hana Bank in Seoul, South Korea, Monday, June 29, 2026. (AP Photo/Lee Jin-man)
An electronic board shows Japan's benchmark Nikkei 225 index, bottom, and exchange rate of the Japanese yen against the U.S. dollar in Tokyo Tuesday, June 30, 2026. (Kenichiro Kojima/Kyodo News via AP)
